Asylia Diagnostics

Foundation date



#Biotechnology / R&D Services


Therapeutic areas

At Asylia Diagnostics we are building a technology platform that will permit a quick and efficient high-resolution profiling of tumor microenvironment, different immune cells and their subtypes, and cell signaling. With the right data at hand, it will unlock an opportunity to discover novel biomarkers and modes of action for investigational drugs.

Upcoming events

Latest news

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    19 hours ago

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody┬« drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022